Thinking Globally: Broadening Cancer Treatment Equity Around the World With Gilberto Lopes, MD, and Samuel Kareff, MD, MPH

In this Fellows Forum interview, Dr. Samuel Kareff interviews Dr. Gilberto Lopes, Chief of the Division of Medical Oncology, Associate Director for the Cancer Center, and Medical Director for International Affairs at the University of Miami, Sylvester Comprehensive Cancer Center. Dr. Lopes shares more about his work in global oncology, including:

  • The story of how he first became interested in global oncology research during his medical training in Brazil
  • The rise of sustainable development goals in the global health agenda
  • The importance of biodirectionality and prioritizing equity in both low-income and high-income settings
  • Organizations that are most invested in democratizing access to drugs internationally, including the Noncommunicable Disease (NCD) Alliance and the Access to Oncology Medicines (ATOM) Coalition
  • Recent research pieces in global oncology, including those looking at biological differences that contribute to outcome disparities
  • The American of Society Clinical Oncology (ASCO)’s contributions to the field of global oncology
  • And more!

About Dr. Lopes and Dr. Kareff

Samuel Kareff, MD, MPH, is a Medical Oncologist and the Outgoing Chief Hematology-Oncology Fellow at the University of Miami’s Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital in Florida. He is soon to enter hybrid practice focusing on thoracic and gastrointestinal cancers. Dr. Kareff has special research interests in health advocacy, public policy, and the development of cancer therapies.

 

Gilberto Lopes, MD, is Chief of the Division of Medical Oncology, Associate Director for the Cancer Center, and Medical Director for International Affairs at the University of Miami, Sylvester Comprehensive Cancer Center. He is currently finishing his term as Editor in Chief of the Journal of Clinical Oncology (JCO) Global Oncology, a post which he has held for almost a decade. His research focuses on anticancer drug development and global oncology. Dr. Lopes has led hundreds of clinical trials, including the groundbreaking KEYNOTE-042 trial which led to the FDA approval of pembrolizumab for lung cancer. He is passionate about cancer control, policy, and health economics and actively works to improve access to cancer therapies in underserved settings.

Related Articles

Responses

Your email address will not be published. Required fields are marked *